anti cd80 pe  (Elabscience Biotechnology)

Journal: Vaccines

Article Title: Peptide Coacervates Promote Cytosolic Delivery of STING Agonists for Cancer Immunotherapy

doi: 10.3390/vaccines14040329

Figure Lengend Snippet: Peptide and cGAMP coacervates facilitate antigen cross-presentation. ( a ) Antigen cross-presentation of BMDCs treated with OVA-SIIN (10 μM), SIIN-4A (10 μM) and cGAMP (2 μM) in indicated formulations for 8 h and stained with PE-SIINFEKL antibody, and then recorded by confocal laser scanning microscope. ( b – e ) Antigen cross-presentation of BMDCs or BMDCs STING KO treatment as panel a, stained with APC-SIINFEKL antibody, and then detected by flow cytometry. ( b , d ) The red dashed line serves as a reference to clearly illustrate the degree of shift across different groups. ( f – h ) CD40, CD80 and CD86 expression of BMDCs treated with OVA-SIIN (10 μM), SIIN-4A (10 μM) and cGAMP (2 μM) in indicated formulations for 24 h and detected by flow cytometry. Data are presented as mean ± SEM, n = 3 independent samples; ns, not significant, **** p < 0.0001 using one-way ANOVA with Tukey’s test.

Article Snippet: ACK Lysis Buffer (E-CK-A105), mouse bone marrow-derived dendritic cells (BMDC) induction and identification kit (XJM003), including antibodies of Elab Fluor 488-CD11c, PE/Cyanine7-CD80, PE-CD86, APC-CD40, were purchased from Elabscience Biotechnology (Wuhan, China).

Techniques: Staining, Laser-Scanning Microscopy, Flow Cytometry, Expressing